What is West Pharmaceutical Services's revenue?

West Pharmaceutical Services (WST) generated $3.2B in revenue over the trailing twelve months, up 11.2% year over year.

Is West Pharmaceutical Services profitable?

West Pharmaceutical Services reported $542.7M in net income over the trailing twelve months, a 16.8% net margin.

What are West Pharmaceutical Services's profit margins?

Gross margin is 36.3% and operating margin is 20.3%, with a 16.8% net margin.

What is West Pharmaceutical Services's earnings per share?

West Pharmaceutical Services's diluted EPS over the trailing twelve months is $7.48.

Where does West Pharmaceutical Services's income statement data come from?

Every line is extracted from West Pharmaceutical Services's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

West Pharmaceutical Services WST Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$3.22B+11.2%	$3.07B+6.3%	$3.02B+4.9%	$2.96B+2.9%	$2.9B-1.1%
Total cost of revenue	$2.05B+8.3%	$1.97B+4.0%	$1.94B+3.8%	$1.92B+3.6%	$1.9B+3.0%
Gross profit	$1.17B+16.8%	$1.1B+10.6%	$1.07B+7.0%	$1.04B+1.7%	$1B-8.1%
Gross margin	36.3%+1.7pp	35.9%+1.4pp	35.6%+0.7pp	35.3%-0.4pp	34.5%-2.6pp
Research and development	$73.8M+8.8%	$74.3M+7.5%	$71M+2.9%	$69.4M-0.7%	$67.8M-1.6%
Selling, general and administrative	$405.1M+19.2%	$393.6M+16.3%	$371.9M+8.4%	$352.7M+1.1%	$339.8M-4.0%
Compensation and benefits	——	——	——	——	——
Occupancy and equipment	——	——	——	——	——
Depreciation and amortization	——	——	——	——	——
Impairment charges	——	——	——	——	——
Other operating expenses	——	——	——	——	——
Operating income	$655M+18.2%	$584.9M+2.6%	$587.9M+2.9%	$581.6M-1.0%	$554.1M-13.9%
Operating margin	20.3%+1.2pp	19%-0.7pp	19.5%-0.4pp	19.6%-0.8pp	19.1%-2.8pp
Interest expense	——	——	——	——	——
Interest income	$18.5M+5.7%	$17.5M-10.7%	$17.2M-28.9%	$17.1M-39.8%	$17.5M-40.5%
Other income (expense), net	-$1M+82.8%	-$1M0.0%	-$11.9M—	-$8.5M—	-$5.8M—
Income from equity method investments	$14.4M+4.3%	$14.4M-2.0%	$12.5M-21.9%	$14.3M-9.5%	$13.8M-15.3%
Income before income taxes	$670.5M+17.9%	$600.9M+2.6%	$604.3M+2.6%	$596.9M-2.4%	$568.6M-14.8%
Income tax expense	$142.2M+23.4%	$121.6M+13.1%	$125.1M+18.9%	$123.5M+20.8%	$115.2M+0.1%
Net income	$542.7M+16.2%	$493.7M+0.2%	$491.7M-1.6%	$487.7M-7.1%	$467.2M-17.8%
Net margin	16.8%+0.7pp	16.1%-1.0pp	16.3%-1.1pp	16.5%-1.8pp	16.1%-3.3pp
Diluted earnings per share	$7.48+17.4%	$6.79+1.5%	$6.75+0.1%	$6.68-5.0%	$6.37-16.0%
Basic earnings per share	$7.52+17.1%	$6.83+1.2%	$6.79-0.3%	$6.72-5.5%	$6.42-16.3%
Weighted-average shares, diluted	290.2M-1.2%	290.8M-1.5%	291.8M-1.7%	292.6M-2.0%	293.8M-2.2%
Weighted-average shares, basic	288.7M-0.9%	289.2M-1.1%	289.9M-1.3%	290.5M-1.6%	291.3M-1.7%
Separation costs	——	——	——	——	——
Adjustment For Amortization	——	——	——	——	——
Pre-tax stock-based compensation cost	——	——	——	——	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1	——	——	——	——	——
Capital investments accrued but not yet paid	——	——	——	——	$48.9M-42.9%
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Dividends declared (in dollars per share)	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——	——
Revenue recognized that was included in deferred income at the beginning of the period	——	——	——	——	——
Depreciation	$174.1M+11.5%	$168.6M+11.1%	$162M+10.5%	$159M+11.9%	$156.2M+13.4%
Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net	——	——	——	——	——
Dividends, Common Stock, Cash	——	——	——	——	——
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——	——
Effective tax rates	——	——	——	——	——
Finance Lease Interest Payment On Liability	——	——	——	——	——
Finance Lease Principal Payments	$1.2M-94.9%	$1.1M-95.3%	$900K-96.2%	$900K-96.1%	$23.5M+11,650%
Finance Lease Right Of Use Asset Amortization	——	——	——	——	——
Gain (Loss), Foreign Currency Transaction, before Tax	——	——	——	——	——
Gain Loss On Fair Value Hedges Recognized In Earnings	——	——	——	——	——
Increase (Decrease) in Contract with Customer, Asset	——	——	——	——	——
Increase (decrease) in contract liabilities and current deferred income	——	——	——	——	——
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital	——	——	——	——	——
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	——	——	——
Interest Income (Expense) And Other Nonoperating (Expense) Income, Net	——	——	——	——	——
Net interest and investment income (loss)	$18.5M+5.7%	$17.5M-10.7%	$17.2M-28.9%	$17.1M-39.8%	$17.5M-40.5%
Lease Cost	——	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$346.8M+30.4%	-$185.1M+70.3%	-$242.3M+67.4%	-$295.2M+57.9%	-$498.6M+24.4%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$257.3M+28.4%	-$285.9M+24.5%	-$314.6M+17.8%	-$333.4M+15.9%	-$359.4M+4.7%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$715.3M+7.6%	$754.8M+15.5%	$693.8M-1.2%	$676.7M-10.1%	$664.6M-12.2%
Number of reportable segments	——	——	——	——	——
Number of restructuring program	——	——	——	——	——
Other comprehensive income/(loss) before reclassifications	——	——	——	——	——
Share of other comprehensive (loss) income from Brookfield Asset Management ULC	——	——	——	——	——
Net gain (loss) on equity affiliate accumulated other comprehensive income, tax	——	——	——	——	——
Operating Lease Payments	——	——	——	——	——
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent	——	——	——	——	——
Other Comprehensive Income Defined Benefit Plans Tax Portion Attributable To Parent	——	——	——	——	——
Foreign currency translation	——	——	——	——	——
Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent	——	——	——	——	——
Cash flow hedges	——	——	——	——	——
Other Comprehensive Income Loss Cash Flow Hedge Reclassification For Discontinuance Before Tax	——	——	——	——	——
Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax Parent	——	——	——	——	——
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax, Parent	——	——	——	——	——
Net investment hedges	——	——	——	——	——
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax	——	——	——	——	——
Other comprehensive income/(loss)	——	——	——	——	——
Other Income (Expense)	-$34.6M+10.1%	-$51.2M-144%	-$42.9M-118%	-$40.4M-93.3%	-$38.5M-78.2%
Other Noncash Income (Expense)	——	——	——	——	——
Other income, net (Note 6)	-$1M+16.7%	-$1M0.0%	-$900K—	-$1.4M—	-$1.2M—
Other income, net	——	——	——	——	——
Payments for Repurchase of Common Stock	——	——	——	$240.8M-63.5%	$427.4M-33.8%
Payments of Ordinary Dividends, Common Stock	$61.8M+3.7%	$61.2M+3.6%	$60.7M+3.6%	$60.1M+3.4%	$59.6M+3.5%
Payment, Tax Withholding, Share-Based Payment Arrangement	$2.8M0.0%	$2.8M-50.9%	$2.8M-50.0%	$2.7M-54.2%	$2.8M-58.8%
Payments to Acquire Property, Plant, and Equipment	$257.3M-28.1%	$285.9M-24.2%	$314.7M-17.4%	$332.7M-15.8%	$357.7M-3.5%
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans	$7M-1.4%	$6.9M-4.2%	$7M-5.4%	$7.1M-2.7%	$7.1M-2.7%
Cash received from option exercises	$14.3M+8.3%	$11.3M-55.7%	$9.7M-61.7%	$11.6M-70.9%	$13.2M-70.8%
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	——	——	——	——	——
Related Party Transaction Purchases From Related Party	——	——	——	——	——
Revenue From Contract With Customer Excluding Assessed Tax	$3.22B+11.2%	$3.07B+6.3%	$3.02B+4.9%	$2.96B+2.9%	$2.9B-1.1%
Right Of Use Asset Obtained In Exchange For Finance Lease Liability	——	——	——	——	——
Right Of Use Asset Obtained In Exchange For Operating Lease Liability	——	——	——	——	——
Property, plant, and equipment additions	——	——	——	——	——
Stock-based compensation	$29.1M+94.0%	$23.8M+27.3%	$21.4M+35.4%	$18.1M+9.0%	$15M-24.2%
Expected volatility	——	——	——	——	——
Weighted-average grant date fair value of stock options (in dollars per share)	——	——	——	——	——
Number of additional shares authorized under the plan (in shares)	——	——	——	——	——
Risk-free rate	——	——	——	——	——
Options granted (in shares)	——	——	——	——	——
Weighted-average dividend yield	——	——	——	——	——
Granted (in shares)	——	——	——	——	——
Short Term Lease Cost	——	——	——	——	——
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	——	——	——	——	——
Average price paid (in dollars per share)	——	——	——	——	——
Number of shares purchased (in shares)	——	——	——	——	——
Treasury stock, value, acquired	——	——	——	——	——
Variable Lease Cost	——	——	——	——	——
EBITDA	$831M+16.5%	$755.7M+4.3%	$752.1M+4.4%	$743M+1.6%	$713M-8.8%
EBITDA margin	25.8%+1.2pp	24.6%-0.5pp	24.9%-0.1pp	25.1%-0.3pp	24.6%-2.1pp
EBIT	$655M+18.2%	$584.9M+2.6%	$587.9M+2.9%	$581.6M-1.0%	$554.1M-13.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about West Pharmaceutical Services.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is West Pharmaceutical Services's revenue?: West Pharmaceutical Services (WST) generated $3.2B in revenue over the trailing twelve months, up 11.2% year over year.
Is West Pharmaceutical Services profitable?: West Pharmaceutical Services reported $542.7M in net income over the trailing twelve months, a 16.8% net margin.
What are West Pharmaceutical Services's profit margins?: Gross margin is 36.3% and operating margin is 20.3%, with a 16.8% net margin.
What is West Pharmaceutical Services's earnings per share?: West Pharmaceutical Services's diluted EPS over the trailing twelve months is $7.48.
Where does West Pharmaceutical Services's income statement data come from?: Every line is extracted from West Pharmaceutical Services's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.